The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Phase II study of oxaliplatin and sorafenib in advanced gastric cancer after failure of cisplatin-fluoropyrimidine-based (PF) treatment.
Rosa Gallego
No relevant relationships to disclose
Marta Martin-Richard
No relevant relationships to disclose
Carles Pericay
No relevant relationships to disclose
Jesus Garcia-Foncillas
No relevant relationships to disclose
Bernardo Queralt
No relevant relationships to disclose
Esther Casado
No relevant relationships to disclose
Jaime Feliu
No relevant relationships to disclose
Iranzazu Vega
No relevant relationships to disclose
Ignacio Juez
No relevant relationships to disclose
Laura Visa
No relevant relationships to disclose
Eugeni SaigĂ­
No relevant relationships to disclose
Xabier Garcia-Albeniz
No relevant relationships to disclose
Agust Barnadas
No relevant relationships to disclose
Joan Maurel
No relevant relationships to disclose